HIV Therapy (ISSN: 1758-4310)
IF(Impact Factor)2018 Evaluation Pending
DescriptionSubstantial advances in the development of antiretroviral drugs and clinical management are being achieved in the field of HIV and AIDS, although many research challenges remain. In recognition of an increased focus on contemporary clinical challenges and disease management issues, Future HIV Therapy (ISSN: 1746-9600) will simply be titled HIV Therapy (ISSN: 1758-4310) from January 2009.
Research into HIV has now been ongoing for a quarter of a century, with the first official case of AIDS being reported in the USA in 1981. Since that time, and the discovery of the causative link with HIV by researchers first in France and then the USA, great strides have been made in understanding the replication cycle, pathogenesis and epidemiology of this virus. However, in spite of the resources, time, money and effort dedicated to AIDS research in that time, AIDS has been responsible for the deaths of more than 25 million people worldwide, of which at least a third have been in sub-Saharan Africa.
There are now some 20 anti-HIV agents available, along with combination therapies, with many more in the development pipeline. In addition to developing more drugs in the established classes, current and future research will focus on new antiviral targets, such as entry, integrase and maturation inhibitors, to augment and possibly replace the available therapeutic armamentarium.
A great deal of funding is also being focused on the development of a preventative HIV vaccine, with the Center for HIV/AIDS Vaccine Immunology being set up by the NIH in 2005, and the Bill & Melinda Gates Foundation donation of US$287 million over 5 years to 16 groups involved in vaccine research. This highlights the position of HIV/AIDS as a top public health priority.
Therefore, the goal for the HIV research community continues to be to develop new treatments to target the virus and any resistant strains that might develop, and also to improve side effects, adherence and education, simplify drug regimens and reduce costs. In addition, the ultimate aim should be the complete eradication of HIV from an infected immune system. HIV Therapy (ISSN: 1758-4310) will keep researchers up-to-date with the significant advances that will take us toward these goals.
Articles published in HIV Therapy include key areas such as:
The molecular basis of HIV infection
Optimal therapeutic approaches, including drug choice and treatment strategies
Potential future viral targets
Summaries evaluating newly approved anti-HIV agents
Postmarketing research, including adverse events and drug safety, pharmacoeconomics and cost–benefit issues in HIV therapy
Epidemiological studies and trends
HIV drug resistance
New and improved diagnostic methods
Vaccine development, prevention measures and prophylaxis
Last modified: 2017-08-06 12:14:08
- No Archives